Pharmaceuticals, Biotechnology and Life Sciences
As Vertex expands deal with NHS England to include Kaftrio in combination with Kalydeco, the cysitc fibrosis patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the European Commission.
Vertex Pharmaceutical said on Friday in a press release that, if Kaftrio combined with Kalydeco is granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease.
–Nonprofit issues challenge to accelerate treatments for every person with CF–
Vertex Pharmaceuticals got approval from the USFDA for Trikafta, for treating cystic fibrosis in patients older than 12
Vertex Pharmaceuticals will move its cystic fibrosis treatment VX-659 and VX-445 into Phase 3, the company said Wednesday, after the initial…
U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.